UBS Maintains Buy on Akero Therapeutics, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on Akero Therapeutics (NASDAQ:AKRO) but has lowered the price target from $83 to $39.
October 12, 2023 | 5:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS maintains a Buy rating on Akero Therapeutics but lowers the price target from $83 to $39.
The news is directly related to Akero Therapeutics. While the maintained Buy rating is positive, the significant reduction in price target could create uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100